Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
6 US States for Fly Fishing - 2Opening Monetary Information: Your Exhaustive Manual for Finding out about Individual budget
- 3Vote In favor of Your Favored Comupter Game
- 4Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- 5Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis
- The most effective method to Recognize a Great Lab Jewel
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
- IDF says up to 90% of Iran’s weapons industry could be hit within days
- Some Americans say they'll go without health insurance as ACA rates spike
- The Best Business visionaries Under 30
- The Most recent Microsoft Surface Star PC: Ideal for Top of the line Planning and Gaming Needs
